Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Oncology

Topics

Medicine

Cancer Oncology

Internal Medicine

Gastroenterology

Pulmonary And Respiratory Medicine

Show all topics

DOI

10.1016/s1470-2045(11)70184-x